Canadian Public Reimbursement of Biosimilars (Referred to as Subsequent Entry Biologics – Sebs – In Canada), an Update

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.03.1999
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy